Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2006, for eXegenics Inc. (Note: The input metadata references "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc., formerly Cytoclonal Pharmaceuticals Inc.). The company has terminated all research and development activities and eliminated scientific staff. Management is currently focused on redeploying residual assets and identifying new business opportunities. As of May 9, 2006, the company had 16,891,101 shares of common stock outstanding and is classified as a shell company.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Expenses | $188,000 | $331,000 |
| Operating Loss | $(188,000) | $(331,000) |
| Net Loss | $(43,000) | $(290,000) |
| Net Loss Attributable to Common Shareholders | $(281,000) | $(524,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.02) | $(0.03) |
| Cash and Cash Equivalents (End of Period) | $8,851,000 | $8,409,000 |
| Net Cash Used in Operating Activities | $(50,000) | $(325,000) |
| Total Assets | $8,984,000 | $9,000,000 (Dec 31, 2005) |
| Total Liabilities | $304,000 | $277,000 (Dec 31, 2005) |
Liquidity: The company holds approximately $8.85 million in cash and cash equivalents, consisting principally of interest-bearing deposits. There is no long-term debt reported.
Material Changes vs. Prior Period
- Expense Reduction: General and administrative expenses decreased by 43% ($143,000) compared to the prior year quarter. This reduction was driven by lower officer salaries ($77,000 decrease), reduced insurance premiums ($31,000), and lower investor relations and legal expenses.
- Improved Loss Position: Net loss attributable to common shareholders improved significantly from $(524,000) in Q1 2005 to $(281,000) in Q1 2006.
- Interest Income: Interest income increased to $145,000 in Q1 2006 from $41,000 in Q1 2005, contributing to a reduction in the overall net loss.
- Accounting Change: The company adopted SFAS No. 123R (Share-Based Payment) on January 1, 2006. This resulted in a recorded pre-tax share-based compensation expense of approximately $1,000 for the quarter, primarily related to board of director options.
Outlook, Risks, and Contingencies
Management Commentary: Management states that historical operating results are not indicative of future trends. The primary objective remains the redeployment of assets and the pursuit of new business opportunities. No specific financial guidance or revenue projections were provided.
Legal Proceedings: A significant contingency exists regarding a lawsuit filed by former employee Dr. Abdel Hakim Labidi. A jury ruled in favor of Dr. Labidi on October 5, 2005, awarding $600,000 for conversion and theft of biological materials. The company has recorded a provision of $250,000 as of December 31, 2005. The final amount due is estimated to be between $250,000 and $750,000, pending a court decision on attorney fees and interest.
Risk Factors: The filing notes no material changes to risk factors previously disclosed in the 2005 Form 10-K. The company has no material exposure to foreign currency exchange rates or derivative instruments.
Investor Verification Checklist
- Legal Liability: Verify the final judgment amount and potential attorney fees related to the Dr. Labidi lawsuit, as the current provision ($250,000) may be insufficient if the upper estimate ($750,000) is realized.
- Cash Burn Rate: Monitor the $50,000 quarterly cash burn from operations against the $8.85 million cash balance to assess runway for asset redeployment efforts.
- Strategic Pivot: Confirm the status of the board committee studying strategic direction and any potential new business acquisitions or asset sales.
- Preferred Stock Obligations: Note the quarterly preferred stock dividend obligation of approximately $238,000, which is deducted to arrive at net loss attributable to common shareholders.
- Subscription Receivable: Review the status of the $300,000 note receivable from a former CEO, which is currently reserved and presented net of collateral value due to missed interest payments.